Achillion Pharmaceuticals Inc. (ACHN) Begins First-in-human Dosing for Hepatitis C Treatment

QualityStocks would like to highlight Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.

In the company’s news yesterday,

Achillion announced that it has begun dosing in a phase 1 clinical trial of ACH-2684 for the treatment of chronic hepatitis C virus (HCV) infection.

“This first-in-human clinical trial will be instrumental in establishing the safety profile of ACH-2684 in humans,” Elizabeth A. Olek, D.O., vice president and chief medical officer of Achillion stated in the press release. “It will also provide Achillion with important preliminary efficacy data against HCV genotypes 1 and 3, and help us to select doses for subsequent clinical development.”

The clinical study is a randomized, double-blind, placebo-controlled trial in which scientists will evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684.

The trial will be conducted in the United States and is designed to enroll up to 78 healthy volunteers and up to 40 HCV-infected patients.

Michael D. Kishbauch, president and CEO Achillion, said the company hopes that it can advance ACH-2684 as a unique pan-genotypic protease inhibitor to be administered once daily.

He also noted that phase 2 trials of the company’s lead inhibitor ACH-1625, is on the horizon.

Today’s announced clinical trial, along with upcoming additional clinical trials, position the company to execute its goal of becoming a leading industry player.

“Furthermore, we expect to shortly launch the 12-week segment of the phase 2 trial of our lead ACH-1625 protease inhibitor, as well as a phase 1 trial of our ACH-2928 NS5A inhibitor. We believe we remain poised to deliver a trio of important HCV clinical milestones near the end of this year, namely, 12-week EVR results on ACH-1625 and human proof-of-concept data on both ACH-2684 and ACH-2928,” Kishbauch stated in the press release. “These are all important components in our ultimate strategy of becoming a leader in the development of HCV combination therapies involving our protease and NS5A inhibitors.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.